Latest News and Press Releases
Want to stay updated on the latest news?
-
Jasper’s stock fell 55% after disclosures that it lacked adequate controls over third-party manufacturers, misstating its compliance and operations.
-
Robbins LLP is Investigating Allegations that Jasper Therapeutics, Inc. (JSPR) Misled Investors Regarding the Commercial Prospects of its Lead Product